CyGene Laboratories Launches StrokeScan™ DNA Analysis

Main Category: Stroke / Neuroprotection
Also Included In: Neurology / Neuroscience;  Medical Devices;  Genetics
Article Date: 23 Jul 2008 - 2:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

CyGene Laboratories Inc. (OTC:CYGE) ("the Company") announced today that it is introducing StrokeScan™, a genetic screening test aimed at identifying high risk individuals who have a family history of stroke, cardiovascular or kidney disease.

Offered at $499, StrokeScan™ analyzes genes that have been associated with the increased risk of stroke and the "alpha-galactosidase A" gene that is responsible for Fabry disease. Fabry disease is a genetic disorder that results in an enzyme deficiency that commonly causes death before age 55 by way of stroke, heart attack or kidney failure. Fabry disease was originally thought to occur in only one in 50,000 people. New scientific evidence, based on newborn screening, suggests that it may be over ten times more common as previously believed, and to occur in one in 3,500 people. Simple biochemical tests currently used to diagnose Fabry miss more than 70% of women and 15% of men having the disease. The average time to arrive at a medical diagnosis after the onset of symptoms presently takes over 10 years.

StrokeScan™ is based on know-how and intellectual properties that CyGene exclusively licensed from Prof. Dr. Arndt Rolfs of the University of Rostock, Germany. Prof. Rolfs is recognized as one of the leading authorities on Fabry disease and heads the largest global study on Stroke in Young Fabry Patients (sifap study, www.sifap.eu).

Martin Munzer, CyGene's president and CEO, said, "StrokeScan™ has the ability to save lives. Genetic screening of people in high risk groups is essential in order to identify and then diagnose Fabry disease accurately and at an early stage. We believe that without this form of screening, over 90% of Fabry disease carriers will die undiagnosed, whereby many lives could be saved if the disease is identified and treated with approved drugs."

For more information about CyGene Laboratories and its products and technologies, visit the Company's Web site at www.CyGeneDirect.com.

About CyGene Laboratories Inc.

CyGene Laboratories Inc., based in Coral Springs, Florida, is a biotechnology company focused on introducing genetic predisposition and diagnostic testing into the general population. With five patents issued, CyGene's scientific expertise is in DNA analysis and diagnostic technologies. Incorporated in 1995, CyGene has been developing technology and introducing products that address the growing demand for genetic knowledge implementation and utilization. CyGene currently markets six DNA predictive genetic test panels in accordance with its patent pending business model, sold direct to consumers and through physicians and other healthcare practitioners. CyGene's process offers customers access to the most updated science, guaranteeing their anonymity and keeping consumers on the cutting edge of genetic discoveries at the lowest possible price. The method allows customers who have purchased a previous genetic test panel a low cost upgrade to their genetic report as new genetic discoveries become available.

Forward-Looking Statements:
The statements made in this news release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Additionally words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include, but are not limited to, when or whether the audits of our financial statements will be completed and audit opinions issued, due to unforeseen circumstances or unforeseen issues that may arise during the course of such audits. CyGene Laboratories Inc. has no duty and undertakes no obligation to update such statements. You should independently investigate and fully understand all risks before making investment decisions.

Source
Martin Munzer
CyGene Laboratories Inc.
www.cygenelabs.com